Acute effects of marijuana smoking on negative and positive affect

Journal of Cognitive Psychotherapy

Volumn 25, Issue 1, 2011, Pages 31-46

  Metrik, Jane ^a   Kahler, Christopher W ^a   McGeary, John E ^a   Monti, Peter M ^a   Rohsenow, Damaris J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Affect; Anxiety; Expectancy; Marijuana; Subjective effects

Indexed keywords

11 HYDROXYDRONABINOL; PLACEBO;

ADULT; ARTICLE; CANNABIS SMOKING; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EFFECT SIZE; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOLOGICAL STIMULATION; PROFILE OF MOOD STATES; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SELF REPORT;

EID: 79955088622     PISSN: 08898391     EISSN: None     Source Type: Journal    
DOI: 10.1891/0889-8391.25.1.31     Document Type: Article

References (69)

1. Aarons, G. A., Brown, S. A., Stice, E., & Coe, M. T. (2001). Psychometric evaluation of the marijuana and stimulant effect expectancy questionnaires for adolescents. Addictive Behaviors, 26, 219-236.
2. Agosti, V., Nunes, E., & Levin, F. (2002). Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. American Journal of Drug Alcohol Abuse, 28, 643-652.
3. Ashton, H., Golding, J., Marsh, V. R., Millman, J. E., & Thompson, J. W. (1981). The seed and the soil: Effect of dosage, personality, and starting state on the response to delta-9-tetrahydrocannabinol in man. British Journal of Clinical Pharmacology, 12, 705-720.
4. Babor, T. F. (2006). The diagnosis of cannabis dependence. In R. A. Roffman, R. S. Stephens, & G. A. Marlatt (Eds.), Cannabis dependence: Its nature, consequences, and treatment (pp. 21-36). New York: Cambridge University Press.
5. Baker, T. B., Piper, M. E., McCarthy, D. E., Majeskie, M. R., & Fiore, M. C. (2004). Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychological Review, 111, 33-51.
6. Barrero, F. J., Ampuero, I., Morales, B., Vives, F., De Dios Luna del Castillo, J., Hoenicka, J., et al. (2005). Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). The Pharmacogenomics Journal, 5, 135-141.
7. Bonn-Miller, M. O., Vujanovic, A. A., Feldner, M. T., Bernstein, A., & Zvolensky, M. J. (2007). Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. Journal of Traumatic Stress, 20, 577-586.
8. Bonn-Miller, M. O., Zvolensky, M. J., & Bernstein, A. (2007). Marijuana use motives: Concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers. Addictive Behaviors, 32, 49-62.
9. Bonn-Miller, M. O., Zvolensky, M. J., Marshall, E. C., & Bernstein, A. (2007). Incremental validity of anxiety sensitivity in relation to marijuana withdrawal symptoms. Addictive Behaviors, 32, 1843-1851.
10. Bradley, M. M., & Lang, P. J. (1994). Measuring emotion: The self-assessment manikin and the semantic differential. Journal of Behavior Therapy and Experimental Psychiatry, 25, 49-59.
11. Buckner, J. D., & Schmidt, N. B. (2008). Marijuana effect expectancies: Relations to social anxiety and marijuana use problems. Addictive Behaviors, 33, 1477-1483.
12. Buckner, J. D., & Schmidt, N. B. (2009). Social anxiety disorder and marijuana use problems: The mediating role of marijuana effect expectancies. Depression and Anxiety, 26, 864-870.
13. Budney, A. J., Moore, B. A., Vandrey, R. G., & Hughes, J. R. (2003). The time course and significance of cannabis withdrawal. Journal of Abnormal Psychology, 112, 393-402.
14. Budney, A. J., Novy, P., & Hughes, J. R. (1999). Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction, 94, 1311-1322.
15. Chait, L. D., Fischman, M. W., & Schuster, C. R. (1985). "Hangover" effects the morning after marijuana smoking. Drug and Alcohol Dependence, 15, 229-238.
16. Chait, L. D., & Perry, J. L. (1992). Factors influencing self-administration of, and subjective response to, placebo marijuana. Behavioral Pharmacology, 3, 545-552.
17. Cooper, Z. D., & Haney, M. (2008). Cannabis reinforcement and dependence: Role of the cannabinoid CB1 receptor. Addiction Biology, 13, 188-195.
18. Cooper, Z. D., & Haney, M. (2009). Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug and Alcohol Dependence, 103, 107-113.
19. Curran, H. V., Brignell, C., Fletcher, S., Middleton, P., & Henry, J. (2002). Cognitive and subjective doseresponse effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology, 164, 61-70.
20. Dennis, M. L., Funk, R., Godley, S. H., Godley, M. D., & Waldron, H. (2004). Cross-validation of the alcohol and cannabis use measures in the Global Appraisal of Individual Needs (GAIN) and Timeline Followback (TLFB; Form 90) among adolescents in substance abuse treatment. Addiction, 99(Suppl. 2), 120-128.
21. D'Souza, D. C., Ranganathan, M., Braley, G., Gueorguieva, R., Zimolo, Z., Cooper, T., et al. (2008). Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology, 33, 2505-2516.
22. First, M. B., Spitzer, R. L, Gibbon, M., & Williams, J. B.W. (2002). Structured Clinical Interview for DSMIV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute.
23. Foltin, R. W., Fischman, M. W., Pedroso, J. J., & Pearlson, G. D. (1987). Marijuana and cocaine interactions in humans: Cardiovascular consequences. Pharmacology, Biochemistry, and Behavior, 28, 459-464.
24. Fride, E., & Russo, E. B. (2006) Neuropsychiatry: Schizophrenia, depression, and anxiety. In E. S. Onaivi, T. Sugiura, & V. Di Marzo (Eds.), Endocannabinoids: The brain and body's marijuana and beyond (pp. 371-382). Boca Raton, FL: Taylor & Francis.
25. Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., et al. (2009). Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry, 66, 95-105.
26. Galen, L. W., & Henderson, M. J. (1999). Validation of cocaine and marijuana effect expectancies in a treatment setting. Addictive Behaviors, 24, 719-724.
27. Haney, M., Ward, A. S., Comer, S. D., Foltin, R. W., & Fischman, M. W. (1999). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl), 141, 395-404.
28. Hart, C. L., Haney, M.,Vosburg, S. K., Comer, S. D., & Foltin, R. (2005). Reinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology, 181, 237-243.
29. Hart, C. L., van Gorp, W., Haney, M., Foltin, R. W., & Fischman, M. W. (2001). Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology, 25, 757-765.
30. Haughey, H. M., Marshall, E., Schacht, J., Louis, A., &. Hutchison, K. E. (2008). Marijuana withdrawal and craving: Influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction, 103, 1678-1686.
31. Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry and Biodiversity, 4, 1770-1804.
32. Ilan, A. B., Gevins, A., Coleman, M., ElSohly, M. A., & de Wit, H. (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behavioural Pharmacology, 16, 487-496.
33. Jones, R. T. (1971). Marijuana-induced "high": Influence of expectation, setting and previous drug experience. Pharmacological Reviews, 23, 359-369.
34. Juliano, L. M., & Brandon, T. H. (2002). Effects of nicotine dose, instructional set, and outcome expectancies on the subjective effects of smoking in the presence of a stressor. Journal of Abnormal Psychology, 111, 88-97.
35. Kirk, J. M., & de Wit, H. (1999). Responses to oral delta-9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacology, Biochemistry, and Behavior, 63, 137-142.
36. Kirk, J. M., Doty, P., & de Wit, H. (1998). Effects of expectancies on subjective responses to oral delta-9-tetrahydrocannabinol. Pharmacology, Biochemistry, and Behavior, 59, 287-293.
37. Lichtman, A. H., & Martin, B. R. (2006). Understanding the pharmacology and physiology of cannabis dependence. In R. A. Roffman, R. S. Stephens, & G. A. Marlatt (Eds.), Cannabis dependence: Its nature, consequences, and treatment (pp. 37-57). New York: Cambridge University Press.
38. Lukas, S. E., Mendelson, J. H., & Benedikt, R. (1995). Electroencephalographic correlates of marijuana-induced euphoria. Drug and Alcohol Dependence, 37, 131-140.
39. Lynskey, M. T., Heath, A. C., Nelson, E. C., Bucholz, K. K., Madden, P. A., Slutske, W. S., et al. (2002). Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychological Medicine, 32, 195-207.
40. Marlatt, G. A., & Rohsenow, D. J. (1980). Cognitive processes in alcohol use: Expectancy and the balanced placebo design. In N. K. Mello (Ed.), Advances in substance abuse: Behavioral and biological research (pp. 159-199). Greenwich, CT: JAI Press.
41. Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature, 418, 530-534.
42. Martin, W., Sloan, J., Sapira, J., & Jasinski, D. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenindate in man. Clinical Pharmacological Therapy, 12, 245-258.
43. McDonald, J., Schleifer, L., Richards, J. B., & de Wit, H. (2003). Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology, 28, 1356-1365.
44. McNair, D., Lorr, M., & Droppleman, L. F. (1971). Profile of mood states. San Diego, CA: Educational and Industrial Testing Service.
45. Metrik, J., Rohsenow, D. J., Monti, P. M., McGeary, J., Cook, T. A. R., de Wit, H., et al. (2009). Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. Experimental and Clinical Psychopharmacology, 17, 217-225.
46. Morgan, C. J. A., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010). Cannabidiol attenuates the appetitive effects of Δ 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology, 1-7.
47. Musty, R. E. (2002). Cannabinoid therapeutic potential in motivation processes, psychological disorders and central nervous system disorders. In E. S. Onaivi (Ed.), Biology of marijuana from gene to behavior (pp. 45-74). New York: Taylor & Francis.
48. Onaivi, E. S., Chakrabarti, A., Gwebu, E. T., & Chaudhuri, G. (1996). Neurobehavioral effects of Ag-THC and cannabinoid (CB1) receptor gene expression in mice. Behavioural Brain Research, 72, 115-125.
49. Parolaro, D., Realini, N., Vigano, D., Guidali, C., & Rubino, T. (2010). The endocannabinoid system and psychiatric disorders. Experimental Neurology. EPub ahead of print.
50. Pertwee, R. G. (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology, 156, 397-411.
51. Phan, K. L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., & de Wit, H. (2008). Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. The Journal of Neuroscience, 28, 2313-2319.
52. Pihl, R. O., Segal, Z., & Shea, D. (1978). Negative expectancy as a mediating variable in marijuana intoxication. Journal of Clinical Psychology, 34, 978-982.
53. Rahn, E. J., & Hohmann, A. G. (2009). Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. The Journal of the American Society for Experimental Neurotherapeutics, 6, 713-737.
54. Robinson, T. E., & Berridge, K. C. (2003). Addiction. Annual Review of Psychology, 54, 25-53.
55. Rohsenow, D. J., & Marlatt, G. A. (1981). The balanced placebo design: Methodological considerations. Addictive Behaviors, 6, 107-122.
56. Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4, 245-259.
57. Russo, E. B., & McPartland, J. M. (2002). Cannabis is more than simply Δ9-tetrahydrocannabinol. Psychopharmacology, 165, 431-432.
58. Schacht, J. P., Selling, R. E., & Hutchison, K. E. (2009). Intermediate cannabis dependence phenotypes and the FAAH C385A variant: An exploratory analysis. Psychopharmacology, 203, 511-517.
59. Schafer, J., & Brown, S. A. (1991). Marijuana and cocaine effect expectancies and drug use patterns. Journal of Consulting and Clinical Psychology, 59, 558-565.
60. Stark-Adamec, C., Adamec, R. E., & Pihl, R. O. (1981). The subjective marijuana experience: Great expectations. The International Journal of the Addictions, 16, 1169-1181.
61. Stinson, F. S., Ruan, W. J., Pickering, R., & Grant, B. F. (2006). Cannabis use disorders in the USA: Prevalence, correlates and co-morbidity. Psychological Medicine, 36, 1447-1460.
62. Sulcova, E., Mechoulam, R., & Fride, E. (1998). Biphasic effects of anandamide. Pharmacology, Biochemistry, and Behavior, 59, 347-352.
63. Ujike, H., & Morita, Y. (2004). New perspectives in the studies on endocannabinoid and cannabis: Cannabinoid receptors and schizophrenia. Journal of Pharmacological Sciences, 96, 376-381.
64. Vogel-Sprott, M., & Fillmore, M. T. (1999). Expectancy and behavioral effects of socially used drugs. In E. I. Kirsch (Ed.), How expectancies shape experience (pp. 215-232). Washington, DC: American Psychological Association.
65. Wachtel, S. R., ElSohly, M. A., Ross, S. A., Ambre, J., & de Wit, H. (2002). Comparison of the subjective effects of delta-9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology, 161, 331-339.
66. Wei, L. J. (1978). Application of an urn model to the design of sequential controlled clinical trials. Journal of the American Statistical Association, 73, 559-563.
67. Witkin, J. M., Tzavara, E. T., & Nomikos, G. G. (2005). A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behavioural Pharmacology, 16, 315-331.
68. Zuardi, A. W. (2008). Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum action. Revista Brasileira de Psiquiatria, 30, 271-280.
69. Zvolensky, M. J., Lewinsohn, P., Bernstein, A., Schmidt, N. B., Buckner, J. D., Seeley, J., et al. (2008). Prospective associations between cannabis use, abuse, and dependence and panic attacks and disorder. Journal of Psychiatric Research, 42, 1017-1023.